Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Peptidases released by necrotic cells control CD8+ T cell cross-priming
Jaba Gamrekelashvili, … , Firouzeh Korangy, Tim F. Greten
Jaba Gamrekelashvili, … , Firouzeh Korangy, Tim F. Greten
Published October 8, 2013
Citation Information: J Clin Invest. 2013;123(11):4755-4768. https://doi.org/10.1172/JCI65698.
View: Text | PDF
Research Article Immunology

Peptidases released by necrotic cells control CD8+ T cell cross-priming

  • Text
  • PDF
Abstract

Cross-priming of CD8+ T cells and generation of effector immune responses is pivotal for tumor immunity as well as for successful anticancer vaccination and therapy. Dead and dying cells produce signals that can influence Ag processing and presentation; however, there is conflicting evidence regarding the immunogenicity of necrotic cell death. We used a mouse model of sterile necrosis, in which mice were injected with sterile primary necrotic cells, to investigate a role of these cells in priming of CD8+ T cells. We discovered a molecular mechanism operating in Ag donor cells that regulates cross-priming of CD8+ T cells during primary sterile necrosis and thereby controls adaptive immune responses. We found that the cellular peptidases dipeptidyl peptidase 3 (DPP-3) and thimet oligopeptidase 1 (TOP-1), both of which are present in nonimmunogenic necrotic cells, eliminated proteasomal degradation products and blocked Ag cross-presentation. While sterile necrotic tumor cells failed to induce CD8+ T cell responses, their nonimmunogenicity could be reversed in vitro and in vivo by inactivation of DPP-3 and TOP-1. These results indicate that control of cross-priming and thereby immunogenicity of primary sterile necrosis relies on proteasome-dependent oligopeptide generation and functional status of peptidases in Ag donor cells.

Authors

Jaba Gamrekelashvili, Tamar Kapanadze, Miaojun Han, Josef Wissing, Chi Ma, Lothar Jaensch, Michael P. Manns, Todd Armstrong, Elizabeth Jaffee, Ayla O. White, Deborah E. Citrin, Firouzeh Korangy, Tim F. Greten

×

Figure 6

DPP-3 and TOP-1 preclude CD8+ T cell priming.

Options: View larger image (or click on image) Download as PowerPoint
DPP-3 and TOP-1 preclude CD8+ T cell priming.
 
Titrated amounts of reco...
Titrated amounts of recombinant DPP-3 (A and B) or TOP-1 (C and D) were added to the cultures of DCs and CD8+ T cells together with the SF from B78OVA-FTheat (A and C) or S8L (B and D), and T cell proliferation was analyzed. Data are representative of 3 independent experiments. Histograms represent T cell proliferation corresponding to A and C. (E and F) SF of B78OVA-FTheat was cultured with DCs and T cells. Titrated amounts of SF from B78-FT cells transfected with control, TOP-1, or DPP-3 shRNA plasmids were added, and T cell activation was analyzed. Data are from 3 independent experiments. (G) γ-irradiated CT26OVA transfectants were cultured for 24 hours alone and then for 72 hours with CFSE-labeled OT-I cells. T cell proliferation was analyzed. Data are representative of 2 independent experiments. *P < 0.05, ***P < 0.001, 1-way ANOVA with Dunnett’s multiple-comparison test (A–D) or with Bonferroni’s paired-comparison test (E and F), or Student’s t test (G).

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts